These results implied that inhibition of EREG/ErbB signaling did not suppress the proliferation of NSCLC, but instead reduced the stemness of NSCLC and hence, re-sensitizing the differentiated NSCLC to chemo-drug. This evidence concerns the gene EGFR and non-small cell lung carcinoma.